<DOC>
	<DOC>NCT01107444</DOC>
	<brief_summary>The purpose of this study is to evaluate the anti-tumor activity of LY2181308 in combination with docetaxel compared to docetaxel alone in patients with non-small cell lung cancer who were previously treated with first line chemotherapy.</brief_summary>
	<brief_title>Study of LY2181308 in Combination With Docetaxel Versus Docetaxel in Patients With Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Patients with nonsmall cell lung cancer with locally or advanced metastatic disease(Stage IIIB or IV at entry) not amenable to curative therapy and who have progressed after 1 line of chemotherapy Measureable disease as defined by response evaluation criteria in solid tumors (RECIST) ECOG Performance status of 0 to 1 Must make available any existing tumor tissue from the primary biopsy Patients with prior radiation may be eligible if they meet certain criteria Adequate bone marrow reserve and organ functioning Women must have a negative pregnancy test and must comply with a highly reliable contraceptive method during and for 6 months after the treatment period. Must not be breastfeeding Men must comply with a contraceptive regimen during and for 6 months after the treatment period Currently enrolled in or discontinued a clinical trial involving an investigational drug/device within the last 30 days. Patients may be permitted to enter treatment before the 30 day waiting period in special circumstances Pregnant or breastfeeding Serious concomitant systemic disorders that would compromise the safety of the patient or the patient's ability to complete the study Second primary malignancy that could affect compliance with the protocol or interpretation of the study results Known allergy or hypersensitivity to docetaxel, taxanes, LY2181308, oligonucleotides, or any component of the formulations Patients with documented central nervous system or brain metastasis at the time of study entry Preexisting neuropathy equivalent to a common terminology criteria for adverse events(CTCAE)code greater than or equal to 2</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
</DOC>